Calpain 10 is a ubiquitously expressed mitochondrial and cytosolic Ca(2+)-regulated
cysteine protease in which overexpression or knockdown leads to
mitochondrial dysfunction and cell death. We previously identified a potent and specific
calpain 10 peptide inhibitor (CYGAK), but it was not efficacious in cells. Therefore, we created a homology model using the
calpain 10 amino acid sequence and
calpain 1 3-D structure and docked CYGAK in the active site. Using this model we modified the inhibitor to improve potency 2-fold (CYGAbuK). To increase cellular efficacy, we created CYGAK-S-phenyl-
oleic acid heterodimers. Using renal mitochondrial matrix CYGAK, CYGAK-OC, and CYGAK-ON had IC(50)'s of 70, 90, and 875 nM, respectively. Using isolated whole renal mitochondria CYGAK, CYGAK-OC, and CYGAK-ON had IC(50)'s of 95, 196, and >10,000 nM, respectively. Using renal proximal tubular cells (RPTC) in primary culture, 30 min exposures to CYGAK-OC and CYGAbuK-OC decreased cellular
calpain activity approximately 20% at 1 μM, and concentrations up to 100 μM had no additional effect. RPTC treated with 10 μM CYGAK-OC for 24 h induced accumulation of
ATP synthase β and NDUFB8, two
calpain 10 substrates. In summary, we used molecular modeling to improve the potency of CYGAK, while creating CYGAK-
oleic acid heterodimers to improve efficacy in cells. Since
calpain 10 has been implicated in
type 2 diabetes and renal aging, the use of this inhibitor may contribute to elucidating the role of
calpain 10 in these and other diseases.